<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03870490</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-5133-106</org_study_id>
    <secondary_id>272201300019C-17-0-3</secondary_id>
    <secondary_id>18-0001</secondary_id>
    <nct_id>NCT03870490</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects</brief_title>
  <official_title>An Open-Label Trial to Assess the Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VenatoRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>VenatoRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, open-label study to assess safety and pharmacokinetics of VNRX-5133
      and cefepime in the epithelial lining fluid in healthy adult male and female subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2019</start_date>
  <completion_date type="Actual">April 1, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)</measure>
    <time_frame>Day 2</time_frame>
    <description>Steady-state plasma PK and disposition of cefepime/VNRX-5133 in the ELF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety as measured by the number of subjects with adverse events</measure>
    <time_frame>Days 1-7</time_frame>
    <description>Number of Subjects with AEs (Assessed via patient report, physical exam, ECGs, vital signs, laboratory investigations, and use of concomitant medications for the treatment of AEs)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VNRX-5133 + cefepime</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-5133 + cefepime</intervention_name>
    <description>IV infusion (3 doses)</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to participate in the trial, give written informed consent, and comply with
             the trial restrictions

          -  Gender: male or female with a negative serum pregnancy test (β-human chorionic
             gonadotropin [β-hCG]) at Screening and Day -1; females may be of childbearing
             potential or of nonchildbearing potential

          -  Age: ≥18 years at Screening

          -  Weight: ≥50 kg

          -  Body mass index (BMI): ≥18 kg/m2 and &lt;30 kg/m2

          -  Normal blood pressure (BP), defined as a systolic value ≥90 mm Hg and ≤140 mm Hg and a
             diastolic value &lt;90 mm Hg (Screening and Day -1)

          -  All values for hematology and clinical chemistry tests of blood and urine are either
             within normal limits of laboratory reporting range (WNL) or defined as permitted
             exceptions

          -  Ability and willingness to abstain from alcohol, from 48 hours (2 days) prior to
             admission to the Clinical Research Center (CRC) until discharge from the CRC

          -  Males who are not surgically sterilized and females of childbearing potential must
             agree to use highly effective methods of contraception during this trial and for 90
             days after the last dose of study drug

          -  All over-the-counter (OTC) medications, health supplements, and herbal remedies (eg,
             St. John's Wort extract) must have been stopped at least 14 days prior to admission to
             the CRC

          -  Suitable veins for cannulation/multiple venipunctures as assessed by the Investigator
             at Screening

        Exclusion Criteria:

          -  Employee of the Contract Research Organization (CRO), CRC, or the Sponsor

          -  Female who is pregnant, lactating, or at risk of becoming pregnant during this trial
             or within 90 days after the last dose of study drug

          -  Male with a female partner who is pregnant or lactating during this trial or planning
             to attempt to become pregnant during this trial or within 90 days after the last dose
             of study drug

          -  Use of any investigational drug or device within 30 days prior to Screening (90 days
             for an injectable biological agent)

          -  Presence of a congenital or acquired immunodeficiency syndrome

          -  Any evidence or history of clinically significant medical abnormalities on PE or
             laboratory assessment

          -  Clinically significant ECG abnormality

          -  Sitting systolic BP &gt;140 mm Hg or diastolic BP &gt;90 mm Hg on a single measurement
             following at least 5 minutes of rest at Screening

          -  History of drug allergy of a severity that required urgent medical treatment such as
             treatment with epinephrine in an Emergency Department

          -  History of any hypersensitivity reaction following administration of a cephalosporin,
             penicillin, or other β-lactam antibacterial drug or any component of VNRX-5133 for
             injection formulation

          -  History of hypersensitivity to lidocaine, midazolam, fentanyl, or other topical
             anesthetics/opioids in similar classes to these agents

          -  Use of prescription or nonprescription drugs, vitamins, or dietary supplements within
             14 days prior to the first dose of study drug

          -  History of donation of &gt;450 mL of blood within 60 days prior to first dose of study
             drug or planned donation before 30 days has elapsed since final dose of study drug

          -  Plasma or platelet donation within 7 days of first dose of study drug or planned
             donation during this trial

          -  Current suspected drug or alcohol abuse as specified in the Diagnostic and Statistical
             Manual of Mental Disorders, Fifth Edition, Text Revision criteria

          -  Recent history of alcohol consumption exceeding 7 drinks/week for females or 14
             drinks/week for men (1 standard drink=5 ounces of wine or 12 ounces of beer or 1.5
             ounces of hard liquor) within 6 months before Screening

          -  Use of tobacco- or nicotine-containing products from Screening through Check Out
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 8, 2019</study_first_submitted>
  <study_first_submitted_qc>March 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2019</study_first_posted>
  <last_update_submitted>May 3, 2019</last_update_submitted>
  <last_update_submitted_qc>May 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

